Clinical trials: Chronic Kidney Disease
Renal Failure, End Stage Renal Disease
Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
Retrospective analysis of performance and treatment data collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter \& Genius 90 Concentrates in acute haemodialysis, haemodynamically instable patients and chronic…
- Conditions
- Renal Failure, End Stage Renal Disease, Acute Renal Failure
- Trial name
- Genius (NCT05282732)
- Where
- 3 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism
A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Approximately 56 participants who are 1 month old to 17 years old will be enrolled in this study. The total duration for this study will be 38 weeks (or up to 42 weeks when participants require a washout period due to prior…
- Trial name
- NCT07890584
- Testing
- PLS240, Standard of Care
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Pathalys Pharma
Anemia
STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients
This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous Mircera for the maintenance of hemoglobin levels in dialysis participants with chronic renal anemia.
- Trial name
- NCT00642850
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 24 sites in Czechia
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease
Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)
The purpose of this study is to look at subject incidence of adverse events.
- Trial name
- NCT00156962
- Testing
- Epoetin alfa DT, Epoetin alfa RB
- Volunteers
- 850 people
- Sponsor
- Amgen
Anemia
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
- Trial name
- NCT00548691
- Testing
- Ferric Carboxymaltose, Standard Medical Care (SMC)
- Where
- United States
- Volunteers
- 513 people
- Sponsor
- American Regent, Inc.
End Stage Renal Disease
A Simplified Lung Ultrasound Guided Management Protocol Of Pulmonary Congestion in Hemodialysis
Pulmonary congestion secondary to volume overload or interstitial tissue inflammation is common in chronic hemodialysis patients.
- Trial name
- NCT06296160
- Testing
- Intervention Group
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Chronic Kidney Disease
A Study of LY3113593 in Participants With Chronic Kidney Disease
This study is not intended to treat anemia of chronic kidney disease but to determine the safety of the study drug, LY3113593. The study will also evaluate how much of the study drug gets into the blood stream, how long it takes…
- Trial name
- NCT02604160
- Testing
- LY3113593
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Renal Anemia in Non-dialysis Chronic Kidney Disease
Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients
To evaluate the rationality of different initial doses of enarodustat for the treatment of anemia in ND-CKD patients
- Trial name
- NCT07079579
- Testing
- Enarodustat 2mg, Enarodustat 3mg, Enarodustat 4mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Chronic Renal Failure, Chronic Kidney Disease
Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA)…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- PEARL 2 (NCT00598442)
- Testing
- peginesatide, Darbepoetin alfa
- Where
- 64 sites in United States, Bulgaria and 8 more
- Volunteers
- 493 people
- Sponsor
- Affymax
Anemia of End Stage Renal Disease
TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
- Trial name
- NCT02378662
- Testing
- MDGN201 TARGTEPO
- Where
- 2 sites in Israel
- Volunteers
- 2 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Kidney Disease, Chronic
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in…
- Trial name
- NCT05213624
- Testing
- BI 764198
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 67 people
- Sponsor
- Boehringer Ingelheim
IgA Nephropathy
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16…
- Trial name
- NefXtend (NCT06712407)
- Testing
- TARPEYO®
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Calliditas Therapeutics AB
Hypertension, Vascular Diseases
SPYRAL GEMINI Pilot Study
The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with…
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
- Trial name
- SPYRAL GEMINI (NCT06907147)
- Testing
- Multi-Organ Denervation Gemini System
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 175 people
- Sponsor
- Medtronic Vascular
End Stage Renal Disease, End Stage Renal Disease on Dialysis
First Evaluation of the Moda-Flx Hemodialysis System™ in Real World Clinical Settings
This is a non-significant risk study utilizing a device cleared for use by the FDA under its 510(k) clearance. Consented patients will complete their usual dialysis treatment under professional care in an ICHD (In-Center…
- Conditions
- End Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Kidney Disease
- Trial name
- NCT06581393
- Testing
- Moda-flx Hemodialysis System
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Diality Inc.
Chronic Kidney Disease
Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants
The study will have 2 independent parts: Part 1 of the study is intended to collect samples for Metabolites in Safety Testing (MIST) analysis after administration of multiple doses of zibotentan.
- Trial name
- NCT04991571
- Testing
- Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Renal Failure
Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy Volunteers
This study is a randomized, open-label, single dosing, 3-treatment, 6-sequence, 3-period, crossover-design study to compare the pharmacokinetics and safety of D113 with CKD-349 in healthy volunteers.
- Trial name
- NCT04952506
- Testing
- CKD-349 F1 Tab., CKD-349 F2 Tab., D113 Tab.
- Where
- South Korea
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Anemia
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
This single arm study will assess the efficacy and safety of subcutaneous Mircera for the correction and maintenance of hemoglobin levels in predialysis patients with renal anemia who are not currently treated with ESA.
- Trial name
- NCT00680563
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 22 sites in Argentina, Brazil and 8 more
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Failure
Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD
The aim of this study is to assess the superiority of the new low sodium peritoneal dialysis (PD) solution PDsol 12 in comparison with a conventional, already marketed solution, Gambrosol trio 40, in the treatment of the…
- Trial name
- PDOne (NCT00794326)
- Testing
- Solution for Peritoneal Dialysis
- Where
- 29 sites in Denmark, France and 3 more
- Volunteers
- 140 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Chronic Kidney Disease, Diabetic Nephropathy
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets (low dose and high dose) compared…
- Trial name
- RADAR (NCT01356849)
- Testing
- Atrasentan
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
End-Stage Renal Disease
L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis
A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile.
- Trial name
- NCT00851838
- Testing
- L-Carnitine
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Iperboreal Pharma Srl
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.